Augustine Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$83.3M
- Investors
-
13
Augustine Therapeutics General Information
Description
Developer of therapeutic drugs designed to treat neuromuscular and neurodegenerative diseases. The company's drugs have the potential to protect from nerve degeneration and promote peripheral myelin repair, enabling healthcare providers to improve the lives of patients and cure them.
Contact Information
Website
www.augustinetx.comCorporate Office
- Gaston Geenslaan 3
- 3001 Leuven
- Belgium
Corporate Office
- Gaston Geenslaan 3
- 3001 Leuven
- Belgium
Augustine Therapeutics Timeline
Augustine Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series A) | 24-Mar-2025 | $83.3M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC | 03-Jan-2023 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 23-Mar-2021 | $1.44M | $4.65M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 16-Dec-2019 | $4.65M | $4.65M | Completed | Startup |
Augustine Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A | ||||||||
| Seed Shares | ||||||||
| Ordinary | 230,826 | $1.39 | $1.39 | 1x | $1.39 | 0.6% | ||
| Seed Shares | 1,861,994 | $1.39 | $1.39 | $1.39 | 4.83% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Augustine Therapeutics Comparisons
Industry
Financing
Details
Augustine Therapeutics Competitors (3)
One of Augustine Therapeutics’s 3 competitors is AviadoBio, a Venture Capital-Backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AviadoBio | Venture Capital-Backed | London, United Kingdom | ||||
| ExeVir | Venture Capital-Backed | Ghent, Belgium | ||||
| Montis Biosciences | Venture Capital-Backed | Leuven, Belgium |
Augustine Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Augustine Therapeutics Patents
Augustine Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026027696-A1 | Thiomethyl carbonyl compounds and use thereof as hdac6 inhibitors | Pending | 31-Jul-2024 | ||
| WO-2024261327-A1 | 2-(heteroaryl-thio)-1-(heteroaryl)ethanone compounds and use thereof as hdac6 inhibitors | Inactive | 21-Jun-2023 | ||
| WO-2024261328-A1 | Amide-amine compounds and use thereof as hdac6 inhibitors | Inactive | 21-Jun-2023 | ||
| AU-2024314277-A1 | Heteroaryl-amine compounds and use thereof as hdac6 inhibitors | Pending | 21-Jun-2023 | ||
| EP-4731216-A1 | Heteroaryl-amine compounds and use thereof as hdac6 inhibitors | Pending | 21-Jun-2023 | C07D409/14 |
Augustine Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Augustine Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Asabys Partners | Venture Capital | Minority | ||
| CMT Research Foundation | Not-For-Profit Venture Capital | Minority | ||
| Jeito | Growth/Expansion | Minority | ||
| Lilly USA | Corporation | Minority | ||
| Newton BioCapital | Venture Capital | Minority |
Augustine Therapeutics FAQs
-
When was Augustine Therapeutics founded?
Augustine Therapeutics was founded in 2019.
-
Where is Augustine Therapeutics headquartered?
Augustine Therapeutics is headquartered in Leuven, Belgium.
-
What is the size of Augustine Therapeutics?
Augustine Therapeutics has 23 total employees.
-
What industry is Augustine Therapeutics in?
Augustine Therapeutics’s primary industry is Drug Discovery.
-
Is Augustine Therapeutics a private or public company?
Augustine Therapeutics is a Private company.
-
What is the current valuation of Augustine Therapeutics?
The current valuation of Augustine Therapeutics is .
-
What is Augustine Therapeutics’s current revenue?
The current revenue for Augustine Therapeutics is .
-
How much funding has Augustine Therapeutics raised over time?
Augustine Therapeutics has raised $93.4M.
-
Who are Augustine Therapeutics’s investors?
Asabys Partners, CMT Research Foundation, Jeito, Lilly USA, and Newton BioCapital are 5 of 13 investors who have invested in Augustine Therapeutics.
-
Who are Augustine Therapeutics’s competitors?
AviadoBio, ExeVir, and Montis Biosciences are competitors of Augustine Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
